secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-07-09T10:00:22+00:00
Accession:  0001193125-26-298979
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics amends loan facility with Oxford Finance, extends Term A draw period to Dec 31, 2026
--------------------------------------------------------------------------------

- Amendment extends availability of remaining $15M Term A loans through Dec 31, 2026; upfront fee of $187,500.
- If full $15M not drawn by Dec 31, 2026, non-utilization fee of 1% of undrawn amount applies.
- If full $15M drawn, Term B loan availability extended to Sep 30, 2027; Term C loans restructured into two $20M tranches with revenue/clinical milestones.
- Minimum revenue covenants begin Q2 2027 or later depending on capital raises; original facility up to $150M with $25M drawn in Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/0001193125-26-298979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/kytx-20260708.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-298979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer